Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01489046 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 297
- Enrollment target
NCT01489046 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 297 participants.
The verdict
NCT01489046, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 297 participants
- Enrollment target
Study Summary
The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects
Interventions
- DRUG Efavirenz
- DRUG BMS-986001
- DRUG Placebo matching with BMS-986001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01489046
The ClinicalTrials.gov registry entry for NCT01489046 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Efavirenz is the first listed.
NCT01489046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01489046 about?
NCT01489046 is a clinical study titled "Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive". The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects
What is the current status of trial NCT01489046?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 297 participants. The study started on 2011-02. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01489046?
The interventions under investigation include: Efavirenz (DRUG), BMS-986001 (DRUG), Placebo matching with BMS-986001 (DRUG).
Who is sponsoring clinical trial NCT01489046?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.